Informative censoring occurs when progression-free survival is the primary end point of a randomized clinical trial and unequal patient dropout is observed between treatment arms owing to poorer tolerance of experimental treatment. Herein we discuss how informative censoring in the experimental arm before criteria for disease progression are met causes bias towards a positive result.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ranganathan, P. & Pramesh, C. S. Censoring in survival analysis: potential for bias. Perspect. Clin. Res. 3, 40 (2012).
Stone, A. M. et al. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Eur. J. Cancer 47, 1763–1771 (2011).
Fleming, T. R., Rothmann, M. D. & Lu, H. L. Issues in using progression-free survival when evaluating oncology products. J. Clin. Oncol. 27, 2874–2880 (2009).
Shih, W. Problems in dealing with missing data and informative censoring in clinical trials. Curr. Control Trials Cardiovasc. Med. 3, 4 (2002).
Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
Piccart, M. et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann. Oncol. 25, 2357–2362 (2014).
Templeton, A. J. et al. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur. J. Cancer 51, 721–724 (2015).
Sun, J. The Statistical Analysis of Interval-Censored Failure Time Data: Statistics for Biology and Health. (Springer, 2006).
Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111–121 (2018).
Ethier, J.L. et al. Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer. Cancer Res. 79, Abstract P4-14-03 (2019).
The authors declare no competing interests.
About this article
Cite this article
Templeton, A.J., Amir, E. & Tannock, I.F. Informative censoring — a neglected cause of bias in oncology trials. Nat Rev Clin Oncol 17, 327–328 (2020). https://doi.org/10.1038/s41571-020-0368-0
A systematic review of the quality of conduct and reporting of survival analyses of tuberculosis outcomes in Africa
BMC Medical Research Methodology (2021)
British Journal of Cancer (2021)